Skip to main content

Encompass Health Corporation (EHC) Stock Analysis

HoldVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Care Facilities

Hold if already holding. Not a fresh buy at $106.50, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).

Encompass Health is the largest U.S. inpatient rehabilitation hospital operator by patients, revenues, and facility count, operating 173 hospitals in 39 states and Puerto Rico with concentrations in Florida and Texas. 2025 revenues were $5.94B; 92% of patients are admitted via... Read more

$106.50+16.3% A.UpsideScore 5.9/10#4 of 27 Medical Care Facilities
Stop $101.02Target $124.17(analyst − 13%)A.R:R 2.1:1
Analyst target$142.73+34.0%11 analysts
$124.17our TP
$106.50price
$142.73mean
$160

Hold if already holding. Not a fresh buy at $106.50, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -2.2%/30d (confirmed downtrend). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost earnings 0.60, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (4/4)
Attractive valuation
Recent Earnings detected in news
Risks
Below 200-MA, MA slope -2.2%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)18.0
P/E (Fwd)15.4
Mkt Cap$9.9B
EV/EBITDA9.4
Profit Mgn10.0%
ROE25.2%
Rev Growth9.0%
Beta
Dividend0.76%
Rating analysts16

Quality Signals

Piotroski F7/9

Options Flow

P/C0.50bullish
IV53%elevated
Max Pain$70-34.3% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicTexas or Florida
    10-K Item 1A: 'particularly in areas such as Texas or Florida where we have a concentration of hospitals and other coastal areas susceptible to tropical storms and in western states susceptible to wildfires'

Material Events(8-K, last 90d)

  • 2026-03-10Item 1.02MEDIUM
    Encompass Health terminated its Sixth Amended and Restated Credit Agreement (2022 Credit Agreement, Barclays as agent) on March 9, 2026, paying off all outstanding amounts. Replaced by 2026 Credit Agreement maturing March 2031 with $1B revolving facility on substantially similar terms.
    SEC filing →
  • 2026-02-20Item 5.02LOW
    Cain Hayes (elected to Encompass Health Board January 30, 2026) appointed to Compensation and Human Capital Committee and Compliance and Quality of Care Committee effective February 19, 2026. Routine committee assignment amendment to prior 8-K.
    SEC filing →
  • 2026-02-02Item 5.02LOW
    Cain Hayes elected to Encompass Health Board of Directors on January 30, 2026. Board determined him independent under NYSE standards. No committee assignment made yet. No arrangement or related party interest cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesMomentum 4.4<4.5Death cross (50MA < 200MA)A.R:R 2.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST EARNINGS 0.60EARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
48 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $98.28Resistance $109.34

Price Targets

$101
$124
A.Upside+16.6%
A.R:R2.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 4.4/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-04-30 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is EHC stock a buy right now?

Hold if already holding. Not a fresh buy at $106.50, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -2.2%/30d (confirmed downtrend). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $124.17 (+16.6%), stop $101.02 (−5.4%), A.R:R 2.1:1. Score 5.9/10, moderate confidence.

What is the EHC stock price target?

Take-profit target: $124.17 (+16.3% upside). Target $124.17 (+16.6%), stop $101.02 (−5.4%), A.R:R 2.1:1. Stop-loss: $101.02.

What are the risks of investing in EHC?

Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).

Is EHC overvalued or undervalued?

Encompass Health Corporation trades at a P/E of 18.0 (forward 15.4). TrendMatrix value score: 8.1/10. Verdict: Hold.

What do analysts say about EHC?

16 analysts cover EHC with a consensus score of 4.4/5. Average price target: $143.

What does Encompass Health Corporation do?Encompass Health is the largest U.S. inpatient rehabilitation hospital operator by patients, revenues, and facility...

Encompass Health is the largest U.S. inpatient rehabilitation hospital operator by patients, revenues, and facility count, operating 173 hospitals in 39 states and Puerto Rico with concentrations in Florida and Texas. 2025 revenues were $5.94B; 92% of patients are admitted via physician referrals from acute-care hospitals following strokes, hip fractures, and neurological conditions.

Related stocks: AVAH (Aveanna Healthcare Holdings Inc) · ADUS (Addus HomeCare Corporation) · ASTH (Astrana Health Inc.) · CON (Concentra Group Holdings Parent) · UHS (Universal Health Services, Inc.)